伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展

doi:10.19803/j.1672-8629.20220441

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (5): 595-600.
DOI: 10.19803/j.1672-8629.20220441

• 综述 • 上一篇

伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展

吕鹏¹, 张京莉¹, 王运红¹, 马芬芬², 张玉³, 黄怡菲^3,*

¹安徽省太和县人民医院药剂科,安徽太和 236600;
²复旦大学附属浦东医院临床药学室,上海 201399;
³华中科技大学同济医学院附属协和医院药学部,湖北武汉 430022

收稿日期:2022-07-29 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: ^*黄怡菲,女,博士,副主任药师,临床药学和临床药理学。E-mail: yf_huang2012@163.com
作者简介:吕鹏,男,硕士,主管药师,抗感染临床药学。
基金资助:
国家重点研发计划资助项目（2017YFC0909900）; 阜阳市卫生健康委科研立项课题青年项目（FY2021-106）

Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole

LYU Peng¹, ZHANG Jingli¹, WANG Yunhong¹, MA Fenfen², ZHANG Yu³, HUANG Yifei^3,*

¹Department of Pharmacy, Taihe Country People’s Hospital, Taihe Anhui 236600, China;
²Department of Clinical Pharmacy, Fudan University Affiliated Pudong Medical Center, Shanghai 201399, China;
³Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430022, China

Received:2022-07-29 Online:2023-05-15 Published:2023-05-16

摘要/Abstract

摘要： 伏立康唑作为广谱抗真菌药物,常作为肺移植术后预防和治疗侵袭性曲霉菌病的首选药物,其耐受性良好、安全有效。随着临床的广泛应用,伏立康唑相关的皮肤鳞状细胞癌的个案报道和研究逐渐增多,常呈侵袭性和多灶性,已成为肺移植受者发生鳞状细胞癌的独立危险因素。本文综述了伏立康唑致肺移植受者出现皮肤鳞状细胞癌的危险因素和潜在机制,为临床合理应用提供一定的参考。

关键词: 伏立康唑, 肺移植, 皮肤鳞状细胞癌, 危险因素, 机制

Abstract: Voriconazole is an effective broad-spectrum antifungal agent characterized by high tolerance, safety and effectiveness that is often used as the first choice for the prevention and treatment of invasive aspergillosis after lung transplantation. With wider clinical application, case reports of voriconazole-related cutaneous squamous cell carcinoma, which is often aggressive and multifocal in nature, are ticking up, making this drug an independent risk factor for squamous cell carcinoma in lung transplant recipients. This article reviews the risk factors and potential mechanisms for the development of squamous cell carcinoma induced by voriconazole in order to provide reference for rational clinical application.

Key words: voriconazole, lung transplant, cutaneous squamous cell carcinoma, risk factors, mechanism

中图分类号:

R978
R994.11

吕鹏, 张京莉, 王运红, 马芬芬, 张玉, 黄怡菲. 伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展[J]. 中国药物警戒, 2023, 20(5): 595-600.

LYU Peng, ZHANG Jingli, WANG Yunhong, MA Fenfen, ZHANG Yu, HUANG Yifei. Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 595-600.

参考文献

[1] TSUNG I, WORDEN FP, FONTANA RJ.A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma[J]. Oncologist, 2021, 26(2): 133-138.
[2] CHANG MS, AZIN M, DEMEHRI S.Cutaneous squamous cell carcinoma: the frontier of cancer immunoprevention[J]. Annu Rev Pathol, 2022, 17: 101-119.
[3] NGUYEN CV, HE Q, RADY PL, et al.Presence of human papillomavirus DNA in voriconazole-associated cutaneous squamous cell carcinoma[J]. Int J Dermatol, 2020, 59(5): 595-598.
[4] HUSAIN S, CAMARGO JF.Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13544.
[5] MINARI A, HUSNI R, AVERY RK, et al.The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants[J]. Transpl Infect Dis, 2002, 4(4): 195-200.
[6] REN JX, NI SD, LI M, et al.Research progress on influencing factors of voriconazole therapeutic drug concentration monitoring[J]. Drugs & Clinic(现代药物与临床), 2021, 36(7): 1545-1548.
[7] DENNING DW, GRIFFITHS CE.Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole[J]. Clin Exp Dermatol, 2001, 26(8): 648-653.
[8] KOLAITIS NA, DUFFY E, ZHANG A, et al.Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation[J]. Transpl Int, 2017, 30(1): 41-48.
[9] Pfizer, Inc. VFEND (voriconazole)[EB/OL]. (2022-10-26)[2023-02-21]. https://www.pfizermedicalinformation.cn/products/package-insert/vfend-injection.
[10] HUSAIN S, CAMARGO JF.Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13544.
[11] MCCARTHY KL, PLAYFORD EG, LOOKE DF, et al.Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy[J]. Clin Infect Dis, 2007, 44(5): e55-e56.
[12] BRUNEL AS, FRAISSE T, LECHICHE C, et al.Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy[J]. AIDS, 2008, 22(7): 905-906.
[13] ANACKER A, FABRÉ G, VAN DORPE J, et al.Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient[J]. Am J Transplant, 2008, 8(4): 877-880.
[14] COWEN EW, NGUYEN JC, MILLER DD, et al.Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole[J]. J Am Acad Dermatol, 2010, 62(1): 31-37.
[15] EPAULARD O, SAINT-RAYMOND C, VILLIER C, et al.Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients[J]. Clin Microbiol Infect, 2010, 16(9): 1362-1364.
[16] IBRAHIM SF, SINGER JP, ARRON ST.Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole[J].Dermatol Surg, 2010, 36(11): 1752-1755.
[17] MORICE C, ACHER A, SOUFIR N, et al.Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report[J]. Case Rep Med, 2010(4): 351084.
[18] WONG JY, KUZEL P, MULLEN J, et al.Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment[J]. Pediatr Transplant, 2014, 18(6): e200-e207.
[19] ZHANG S, NEUJAHR DC, ZWALD FO.Recurrent and metastatic squamous cell carcinoma in lung transplant recipient on voriconazole: lessons learned[J]. JAAD Case Reports, 2015, 1(6): S12-S15.
[20] LI AW, LALOR LE, BELLODI SF, et al.A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment[J]. Pediatr Dermatol, 2018, 35(3): e165-e169.
[21] DUSENDANG JR, CARLSON E, LEE DS, et al.Cohort and nested case-control study of cutaneous squamous cell carcinoma in solid organ transplant recipients by medication[J]. J Am Acad Dermatol, 2022, 86(3): 598-606.
[22] VAJDIC CM, VAN LEEUWEN MT.Cancer incidence and risk factors after solid organ transplantation[J]. Int J Cancer, 2009, 125(8): 1747-1754.
[23] GARRETT GL, BLANC PD, BOSCARDIN J, et al.Incidence of and risk factors for skin cancer in organ transplant recipients in the United States[J]. JAMA Dermatol, 2017, 153(3): 296-303.
[24] NOBEYAMA Y, UMEZAWA Y, ASAHINA A.Risk of squamous cell carcinoma in immunosuppressed patients with voriconazole-related actinic keratosis[J]. J Dermatol, 2022, 49(11): 1168-1172.
[25] VADNERKAR A, NGUYEN MH, MITSANI D, et al.Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients[J]. J Heart Lung Transplant, 2010, 29(11): 1240-1244.
[26] FEIST A, LEE R, OSBORNE S, et al.Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole[J]. J Heart Lung Transplant, 2012, 31(11): 1177-1181.
[27] SINGER JP, BOKER A, METCHNIKOFF C, et al.High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients[J]. J Heart Lung Transplant, 2012, 31(7): 694-699.
[28] ZWALD FO, SPRATT M, LEMOS BD, et al.Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation[J]. Dermatol Surg, 2012, 38(8): 1369-1374.
[29] MCLAUGHLIN JM, EQUILS O, SOMERVILLE KT, et al.Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients[J]. Transpl Infect Dis, 2013, 15(4): 329-343.
[30] ELNAHAS S, OLSON MT, KANG P, et al.Factors associated with skin cancer in lung transplant recipients: a single-center experience[J]. Clin Transplant, 2019, 33(12): e13718.
[31] HAMANDI B, FEGBEUTEL C, SILVEIRA FP, et al.Voriconazole and squamous cell carcinoma after lung transplantation: a multicenter study[J]. Am J Transplant, 2018, 18(1): 113-124.
[32] MANSH M, BINSTOCK M, WILLIAMS K, et al.Voriconazole exposure and risk of cutaneous squamous cell carcinoma, Aspergillus colonization, invasive Aspergillosis and death in lung transplant recipients[J]. Am J Transplant, 2016, 16(1): 262-270.
[33] XIANG LP, GONG WJ, WU SL, et al.Research advances of liver injury inducedby triazole antifungal agents[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(14): 1475-1480.
[34] SWANSON HI.Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective[J]. Chem Biol Interact, 2004, 149(2-3): 69-79.
[35] ONA K, OH DH.Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A[J]. Br J Dermatol, 2015, 173(3): 751-759.
[36] BERGE M, GUILLEMAIN R, TRÉGOUET DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients[J]. Eur J Clin Pharmacol, 2011, 67(3): 253-260.
[37] LEE V, GOBER MD, BASHIR H, et al.Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress[J]. Exp Dermatol, 2020, 29(1): 29-38.
[38] LIU MM, ZHU YJ, WANG X, et al.A meta-analysis on the relationship between COX-2 and skin cancer development[J]. Journal of Harbin Medical University(哈尔滨医科大学学报), 2016, 50(1): 85-89.
[39] IKEYA S, SAKABE JI, YAMADA T, et al.Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation[J]. Sci Rep, 2018, 8(1): 5050.

伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展

Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[3]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[4]	杨珍珍, 常成, 高娜, 张晓林, 宋银森, 刘颖, 范天黎. 基于网络药理学和体外研究探讨木犀草素抑制食管鳞状细胞癌的分子机制[J]. 中国药物警戒, 2023, 20(9): 992-1001.
[5]	何佳, 金艳, 赵玉洋, 周骏辉, 李晓琳, 袁媛, 付璐. 有毒中草药炮制减毒方法研究进展[J]. 中国药物警戒, 2023, 20(9): 1064-1070.
[6]	张冰, 萨日娜, 张晓朦, 张丹, 林志健, 王雨. 药源性心脏毒性研究进展[J]. 中国药物警戒, 2023, 20(8): 841-847.
[7]	李亚梅, 水荣. 托法替尼治疗幼年特发性关节炎研究进展[J]. 中国药物警戒, 2023, 20(8): 956-960.
[8]	陈林珍, 王璇, 张晓朦, 马志强, 陆珊, 吴嘉瑞, 赵崇军, 张冰. 基于斑马鱼模型的杠柳毒苷肝毒性评价[J]. 中国药物警戒, 2023, 20(7): 742-748.
[9]	苏月芬, 郑婧柔, 宫贺, 谢广通, 张洁, 赛春梅. 乳腺结重痛轻凝胶贴膏的成型性及治疗乳腺增生作用机制研究[J]. 中国药物警戒, 2023, 20(7): 783-790.
[10]	黄翠丽, 高奥, 王嘉熙, 郭海丽, 徐晓涵, 程吟楚, 郭代红. 抗菌药物相关血小板减少症的自动监测与评价研究[J]. 中国药物警戒, 2023, 20(7): 807-811.
[11]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[12]	胡碧原, 汪静, 郑微旗, 胡宏平, 陈泳伍. 注射用伏立康唑致自杀倾向与感觉异常1例分析[J]. 中国药物警戒, 2023, 20(4): 469-472.
[13]	李盟, 李容容, 刘成海. 中草药引起肝损伤的临床诊治与用药[J]. 中国药物警戒, 2023, 20(2): 127-131.
[14]	王嘉熙, 郭代红, 张博, 李伯妍, 郭海丽. 116097例氟比洛芬酯用药人群的急性肾损伤自动监测研究及危险因素分析[J]. 中国药物警戒, 2023, 20(2): 201-205.
[15]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.